Psychedelic Retreats: Navigating Unregulated Growth, Safety Concerns, and Legal Complexities

POLICY WIRE — Washington, D.C. — A significant surge in interest regarding the potential therapeutic benefits of psychedelic substances has spawned a new industry: specialized psychedelic retreats.

These multi-day programs, offered by hundreds of providers worldwide, allow participants to pay for drug-assisted experiences, purportedly fostering psychological healing, personal development, and various other advantages. While many establishments claim to implement robust safety protocols, experts caution about the inherent “potential for physical, psychological, and interpersonal harms,” as noted by researchers in a recent JAMA Network Open paper.

The Unregulated Landscape of Psychedelic Experiences

Currently, no psychedelics are federally approved for therapeutic use in the United States, although this regulatory landscape may soon shift. A recent executive order signed by President Donald Trump has directed the Food and Drug Administration (FDA) to expedite reviews of psychedelics demonstrating promise for conditions such as post-traumatic stress disorder (PTSD).

This order also instructs law enforcement agencies to relax restrictions on any psychedelic subsequently approved by the FDA. However, the drug MDMA, which was previously considered by the FDA for PTSD treatment, faced rejection in 2024 due to unresolved concerns regarding its safety and overall effectiveness.

Dr. John Krystal, a psychiatrist at the Yale School of Medicine and a long-time observer of the field, stresses that psychedelic interventions should be regarded as “a serious medical procedure that carries risks that must be carefully managed.” Industry professionals, however, assert that contemporary retreats offer a safer environment compared to the clandestine operations of past decades.

“The increasing visibility of psychedelics has directly fueled greater demand for these specialized retreats,” explained Brad Burge, who possesses nearly two decades of experience with psychedelic non-profits, pharmaceutical companies, and retreat operators. He added that this expanding market has enabled retreats to broaden their services, recruit more medical and coaching staff, and prioritize safety measures to an unprecedented degree.

Legality, Global Operations, and Lack of Standards

In the U.S., psychedelic retreats largely operate outside federal law. The vast majority of substances offered, including magic mushrooms, ayahuasca, MDMA, and LSD, remain illegal under federal statutes. Some retreat organizations might inaccurately claim protection under rare religious exemptions for traditional psychedelic use; however, only a handful of groups, like the Native American Church which utilizes peyote, have formally secured such legal status.

Consequently, many retreats are established in countries where psychedelics face fewer restrictions, such as Peru and Brazil. In these nations, substances like ayahuasca, a potent psychedelic concoction from Amazonian plants, have been an integral part of Indigenous cultural practices for centuries. Irrespective of their operational location, experts lament the absence of universal industry standards or regulatory frameworks governing participant screening, preparation, or post-experience monitoring.

“Without regulation, the quality of care one might receive becomes highly questionable,” stated Joshua White, who founded the Fireside Project, which operates a hotline for individuals encountering difficulties during psychedelic experiences. He expressed concern over a potential “race to the bottom where there is no liability or accountability.”

Evaluating Safety Protocols and Staff Credentials

With virtually no centralized oversight, prospective attendees bear the sole responsibility of meticulously researching and vetting various retreat options. “It is critically important for anyone considering a psychedelic retreat to conduct thorough research, engaging directly with organizers and facilitators to gather comprehensive information about the offerings and operational methods,” advised Amy McGuire, a biomedical ethicist at Baylor College of Medicine and a co-author of the aforementioned JAMA Network Open study.

McGuire and her research team documented a wide array of practices, noting that some companies facilitate the use of multiple psychedelic drugs over the course of their retreats. While many retreats claim to have health professionals on-site, their specific roles and responsibilities are often ill-defined. Troublingly, in some scenarios, these professionals have been observed partaking in psychedelics alongside participants, potentially compromising their ability to respond effectively in an emergency.

When assessing a retreat, critical inquiries include:

• Do staff members possess adequate training and equipment to manage medical emergencies?
• Is a medical facility located nearby, and is reliable transportation readily available?
• Do staffers dedicate sufficient time to prepare participants for the experience and assist them in processing it afterward?

Websites that compile user reviews, such as Retreat.guru, can serve as a valuable resource for gathering this essential information.

Read More: Thailand & Mekong Region Grapple with Severe Forest Fires, Air Pollution Crisis

Inadequate Medical Screening and Medication Risks

One of the most vital safety measures occurs before any retreat commences: thoroughly screening out individuals with serious medical conditions for whom psychedelics are contraindicated. The study revealed that over half of the surveyed retreats excluded participants with mental illnesses like schizophrenia. However, all retreats relied on potential clients to truthfully disclose their medical histories.

“Psychedelic drugs may worsen symptoms of psychotic disorders, such as schizophrenia,” remarked Dr. Krystal, who was not involved in the new research. “It is important that patients are carefully screened to ensure that appropriate patients enter treatment.”

The reliance on self-disclosure poses significant risks, as individuals suffering from severe conditions might intentionally withhold information if they fear it could prevent their participation. McGuire noted, “When someone is truly desperate and believes something could help them, there’s a strong incentive not to be entirely truthful.”

Another potentially dangerous practice is the common requirement or recommendation for attendees to discontinue certain medications, including antidepressants, before using psychedelics. These “washout periods” can range from a single day to six weeks. Medical experts warn that safely tapering off antidepressants like Prozac can demand six to twelve weeks and necessitates professional medical supervision.

“Patients must understand that discontinuing their medication significantly elevates their risk of symptom recurrence or exacerbation,” cautioned Dr. Jeffrey Lieberman, a psychiatrist at Columbia University. “They should be continuously monitored to prevent adverse outcomes.”

The rationale for halting antidepressants stems from research suggesting that combining these drugs with psychedelics might lead to excessive levels of serotonin, a brain chemical crucial for mood, sleep, and other functions. However, retreat operators may also be motivated by a desire to ensure that existing medications do not diminish the intensity of the psychedelic experience. “There’s a business rationale for wanting people to have the maximum experience when they show up and they’re paying for these retreats,” McGuire concluded.